Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
| Revenue (TTM) | $56.69B |
| Gross Profit (TTM) | $42.51B |
| EBITDA | $23.10B |
| Operating Margin | 34.60% |
| Return on Equity | 30.30% |
| Return on Assets | 10.20% |
| Revenue/Share (TTM) | $29.64 |
| Book Value | $21.86 |
| Price-to-Book | 6.36 |
| Price-to-Sales (TTM) | 4.66 |
| EV/Revenue | 5.41 |
| EV/EBITDA | 13.65 |
| Quarterly Earnings Growth (YoY) | -17.00% |
| Quarterly Revenue Growth (YoY) | 0.80% |
| Shares Outstanding | $1.90B |
| Float | $1.86B |
| % Insiders | 0.01% |
| % Institutions | 7.27% |
Volatility is currently expanding
Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.
Legend Biotech on Tuesday appointed longtime Novartis executive Ingrid Zhang as its CEO, effective immediately, banking on an industry veteran to steer its expansion beyond blockbuster cancer therapy Carvykti.
Novartis investors are set to step up scrutiny of the Swiss group's dealmaking strategy after setbacks to drugs it acquired through mergers and acquisitions hit its shares, raising concerns about its pipeline.
A major shareholder in Novartis has called for a shake-up of the Swiss drugmaker's board to improve corporate governance after its shares suffered a record fall this week following back-to-back trial setbacks.
NVS' del-desiran fails the HARBOR study's primary endpoint, adding to recent pipeline setbacks as investors await next steps.
Novartis shareholders awoke to a more than 12.5% decline at open on September 8, 2026, after the Company reported that its Phase 3 HARBOR study of del-desiran and Phase 3 HORIZON study of pelacarsen did not meet their respective primary endpoints. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of NVS investors.
Dyne Therapeutics remains a Buy despite a 16% selloff triggered by Novartis' DM1 trial failure, which heightened platform-wide clinical risk perceptions. The Novartis HARBOR trial failure challenges the core RNA-targeting therapeutic thesis, raising doubts about translating biomarker gains into functional benefit for DYN's DM1 and DMD programs. DYN's lead asset, z-rostudirsen, faces regulatory and confirmatory risks, with FDA approval likely but long-term value now more uncertain due to functional outcome concerns.
A failed cholesterol trial from Novartis (NYSE:NVS | NVS Price Prediction) is dragging the Lp(a) drug class lower and hitting Amgen (NASDAQ:AMGN) harder than any large-cap peer in Tuesday trading.
Biopharma stocks are dominating the unusual options volume list today, after a high-profile clinical trial failure from Novartis AG (NYSE:NVS) sent shockwaves through the sector.
Novartis AG (ADR) (NYSE:NVS) shares fell as much as 10% after the company's del-desiran failed to meet the primary endpoint in its pivotal Phase 3 HARBOR study evaluating the drug in myotonic dystrophy type 1. The study did not show a statistically significant improvement over placebo on video hand opening time, a novel measure of hand myotonia that served as the trial's primary endpoint.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on NVS and any ticker you trade — then tracks every position and per-strategy win rate.
